 Immuron Limited NASDAQ: IMRN has received funding of A6.2 4.45 million from the U.S Department of Defense to examine a dosing regimen for Travelan more suited for use by the military. The Company has received A4.8 million funding from the U.S. Department of Defense for Travelan and A1.4 million from the U.S Naval Medical Research Center to support the Travelan clinical development effort. 